Assay Prediction Pathology Clinical Features
Tissue of Origin Veridex Histology IHC Age/Sex Sites of Metastasis Response to Treatment Survival (mo)
Sarcoma Ovarian PD carcinoma vimentin+, NSE+, synaptophysin+,  CD117+, HMB45-, LCA-, chromogranin-,  actin-, desmin-, Pan CK-, EMA-, S100- 40/F abdomen, pelvis, liver PD 9
Sarcoma Other Adenocarcinoma None 56/M abdomen, liver SD 24
Sarcoma Other PD carcinoma CK7+, EMA+, CK20-, TTF1-, PLAP- 61/M lung, lymph nodes PD 12
Sarcoma Other PD carcinoma AE1/AE3+, CK20+, NSE+, CK7-, CD30-, desmin-, synaptophysin-, EMA- 35/M lung, liver, lymph nodes PR 6
Sarcoma Other PD carcinoma CK+, S100-, HMB45- 86/F pericardial effusion, adrenal gland, liver SD 5
Sarcoma Unsuccessful Adenocarcinoma None 65/M liver SD 9
Table 6 : Clinicopathologic Characteristics of Patients with Sarcoma Predictions (n = 6)